Here’s the latest instalment in our news updates from Blackford Platform Partners.
In February, medical 3D printing specialist Axial3D published two new case studies showcasing how the company supports cardiac surgeons to transform care for their patients and conduct faster and safer valve replacement. The company also published a handy myth-busting guide to 3D printing in spine surgery.
AI-powered breast health solution provider Densitas published a new blog on short-term breast cancer risk models that shows how artificial intelligence may be poised to finally move the needle in precision breast cancer risk assessment.
Visualization and analytical solutions developer Imaging Biometrics participated in the second annual GliMR 2.0 COST Action meeting, which aims to provide a better understanding of glioma pathology and improved treatment strategies. The company also revealed it will soon be releasing a beta-version of an automated workflow to delineate areas of non-tumor from tumor in regions of contrast enhancement in brain lesions.
Medical diagnostic provider MaxQ has secured regulatory approval for Accipio Ax in the EU and Australia, and is now FDA-pending in the US. Accipio Ax, provides automatic, rapid, highly accurate slice-level annotation and prioritization of suspected ICH in CT non-contrast imaging.
Musculoskeletal AI solutions developer Image Biopsy Lab was announced as the winner of the Best New Radiology Vendor award at the 2021 EuroMinnies. The company told us, “It’s a great honour for the team to be recognized by such a well-known professional community. This emphasizes the importance of digital transformation in radiology that brings early detection and prevention of musculoskeletal diseases to a new level.”
Medical imaging enhancement specialist Subtle Medical announced a new webinar, scheduled for March, which is designed to help potential customers understand the use of SubtleMR. In addition, Subtle Medical was mentioned in Dr. Shah Islam’s article in Rad Magazine, highlighting SubtleMR’s “significant improvement in image quality while reducing acquisition time for MRI.” He also referred to the company’s SubtleGAD product (still in its research phase) and its ability to reduce the Gadolinium contrast needed for contrast-enhanced MRI to 10% with no reduction in diagnostic quality.
Enhanced imaging AI firm Qure.ai announced it will be presenting at ECR 2021, the annual meeting of the European Congress of Radiology. The company will be showcasing its range of lung care and critical care solutions.
Lung analysis firm VIDA hosted a webinar on wood smoke and lung health, based on the #1 AuntMinnie article from RSNA 2020. In addition, the company was interviewed for stories in Forbes and STAT Health magazines looking at AI in lung health and FDA clearances related to AI.
Imaging AI specialist icometrix announced the expansion of its icobrain portfolio with icobrain cva, an ischemic stroke solution. The fully-automated, CE-marked and FDA-cleared software solution for the quantitative assessment of tissue perfusion on CT, provides physicians with fast, fully automated, and state-of-the-art insights.
icometrix also featured in a special report from Health Europa, covering early treatment escalation, patient-centricity in the care pathway, and how it is done. And the company presented two ePosters during the 6th annual ACTRIMS Forum – one dedicated to the MRI in MS survey results, and another exploring the value of brain age in MS.
Finally, medical imaging software firm Resonance Health announced that it has now received both Australian TGA and European CE Mark clearance for HepaFat-AI, its fully automated AI software that assesses liver fat.
Stay tuned for more partner news next month!